1. Home
  2. ENB vs MRNA Comparison

ENB vs MRNA Comparison

Compare ENB & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enbridge Inc

ENB

Enbridge Inc

N/A

Current Price

$47.61

Market Cap

106.7B

Sector

Energy

ML Signal

N/A

Logo Moderna Inc.

MRNA

Moderna Inc.

N/A

Current Price

$223.15

Market Cap

91.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENB
MRNA
Founded
1949
2010
Country
Canada
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.7B
91.2B
IPO Year
1998
2018

Fundamental Metrics

Financial Performance
Metric
ENB
MRNA
Price
$47.61
$223.15
Analyst Decision
Buy
Hold
Analyst Count
24
23
Target Price
$50.86
★ $158.47
AVG Volume (30 Days)
4.2M
★ 13.6M
Earning Date
11-06-2026
11-06-2026
Dividend Yield
★ 5.81%
N/A
EPS Growth
N/A
★ 21.77
EPS
★ 1.99
N/A
Revenue
★ $65,194,000,000.00
$19,263,000,000.00
Revenue This Year
$40.44
$24.04
Revenue Next Year
N/A
$10.63
P/E Ratio
$24.18
★ N/A
Revenue Growth
N/A
★ 4.29
52 Week Low
$45.03
$22.28
52 Week High
$58.45
$280.80

Technical Indicators

Market Signals
Indicator
ENB
MRNA
Relative Strength Index (RSI) 45.65 49.76
Support Level $46.38 $181.02
Resistance Level $49.62 $254.48
Average True Range (ATR) 0.73 18.70
MACD -0.08 -2.24
Stochastic Oscillator 36.67 43.41

Price Performance

Historical Comparison
ENB
MRNA

About ENB Enbridge Inc

Enbridge owns extensive midstream assets that transport hydrocarbons across the US and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also operates regulated natural gas utilities in the US and Canada, including Canada's largest natural gas distribution company. The firm has a small renewable energy portfolio primarily focused on onshore and offshore wind projects.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: